LivaNova PLC $LIVN Shares Sold by Bayforest Capital Ltd

Key Points

• Bayforest Capital Ltd significantly reduced its holdings in LivaNova PLC by **95.8%**, now owning only 634 shares valued at $29,000.
• LivaNova's recent earnings report showed an EPS of **$1.05**, surpassing analyst estimates of **$0.84**, with a year-over-year revenue increase of **10.6%**.
• Analysts have mixed opinions on LivaNova, with five giving it a **Buy** rating and Barclays raising its price target from **$55.00 to $58.00**.

Bayforest Capital Ltd reduced its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 95.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 634 shares of the company's stock after selling 14,399 shares during the period. Bayforest Capital Ltd's holdings in LivaNova were worth $29,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Amundi increased its stake in LivaNova by 7.2% during the 1st quarter. Amundi now owns 196,435 shares of the company's stock worth $7,362,000 after buying an additional 13,142 shares during the period. GAMMA Investing LLC increased its stake in LivaNova by 2,299.7% during the 1st quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock worth $344,000 after buying an additional 8,394 shares during the period. Harbor Capital Advisors Inc. increased its stake in LivaNova by 20.3% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 102,165 shares of the company's stock worth $4,599,000 after buying an additional 17,252 shares during the period. EP Wealth Advisors LLC purchased a new stake in LivaNova during the 1st quarter worth approximately $293,000. Finally, Hsbc Holdings PLC increased its stake in LivaNova by 13.4% during the 1st quarter. Hsbc Holdings PLC now owns 6,666 shares of the company's stock worth $258,000 after buying an additional 790 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Trading Down 0.3%

NASDAQ LIVN opened at $53.73 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The firm's fifty day moving average price is $54.30 and its 200 day moving average price is $46.37. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -13.81 and a beta of 0.95. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $58.91.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. The firm had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company's revenue was up 10.6% on a year-over-year basis. During the same period last year, the firm posted $0.93 EPS. On average, sell-side analysts expect that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on LIVN. The Goldman Sachs Group set a $55.00 target price on shares of LivaNova and gave the stock a "neutral" rating in a research note on Wednesday, October 1st. Barclays increased their price objective on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Needham & Company LLC restated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a report on Wednesday, September 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of LivaNova in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $59.71.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.